Tweets by @pharma_BI and @AVIVA1950 @ 2020 State of Possible Conference, MassBio’s VIRTUAL Annual Meeting, August 26 – 27, 2020
Reporter: Aviva Lev-Ari, PhD, RN
Real Time press coverage: Aviva Lev-Ari, PhD, RN
2020 State of Possible Conference, MassBio’s VIRTUAL Annual Meeting, August 26 – 27, 2020
Real Time press coverage: Aviva Lev-Ari, PhD, RN
Susan Hockfield President Emerita
Funding start ups: For Women founded and more women on boards increased to 25% signed by VC Association to track Draw on more of our TALENTED people as advantages to be drown action to invent a better future
Susan Hockfield President Emerita, MIT Faculty founding of companies: 56 companies only 2 founded by Women: Inclusion of Women and Black impact GDP and innovations Bootcamp for Women from the Lab to the Market place
Susan Hockfield President Emerita, MIT Inhaling of particles Volatile organic nano particles can be exhaled for the diagnosis Future Founders Initiative: Data, Approaches, Implementation
Susan Hockfield President Emerita, MIT Convergence technology in Cancer: Diagnosis is still two late: Synthetic Biomarkers: Disease specifics enzymes in nano particles used in diagnosis of cancer cells – urine based Test for cancer
Susan Hockfield President Emerita, MIT 21st Century: Partless Biology – DNA, RNA: Biology and Engineering 2.0 Pathways, water, 2.0 Technologies for Diagnostics for COVID-19: is frustrating Healthcare Cost: Diagnostics too late and too expensively
Susan Hockfield President Emerita, MIT Regional advantage: Collaborations among industry and academia. Biotech – emerging technologies cusp: Biology convergence with Engineering: sweet spot resources to be used more productively
Thomas McCourt President Ironwood Pharmaceuticals, Inc. Clinical trials many are STUCK – solve problems calls for adoption of all companies to digital platforms Entrepreneurial spirit in Kendall square took away the prime position of CA Biotech
Thomas McCourt President Ironwood Pharmaceuticals, Inc. GI disease in Patients – My Gi Health started in NIH – symptoms of GI diseases GI entrepreneurs to build a smart e-Tool to analyze the GI Symptoms few thousand Patients
Nick Dougherty Managing Director MassChallenge HealthTech Around the World communities, MA Biotech infrastructure MassChallenge HealthTech: In Mexico, in Israel in Switzerland Becoming virtual instantly in MARCH 2020 More locations pick up scale up
Naomi Fried Founder CEO Health Innovation Strategies MA best Hospitals: MGH-BWH, Beth Israel-Lahey Clinic, Stuart BC/BS Medical Schools Clusters in Biotech & Digital Health Counsel Definition of Community changed in the COVID-19 Era
Stephen Bernstein McDermott Will & Emery LLP Virtual Bench science Life sciences Products; Deploying a compound, provider responsible for the cost or how the Reimbursement will work Consumer & Patients: Specialty Pharmacy collaborations by planning
Stephen Bernstein McDermott Will & Emery LLP Webinars and Zooms allows communication we will see more innovations – Flatten the World Greater isolation US is expected to lead collaborate is NOW home based no travel creative Virtual Clinical Trials
Renée Deehan-Kenney PhD, VP, QuartzBio Precision Medicine Group Network biology modeling – helps inform chemistry models: Cell line in Mice translation to Human in pancreatic cancer cell line Pessimistic view: Long way to go end point most time
Renée Deehan-Kenney PhD, VP, QuartzBio Precision Medicine Group Network biology modeling – helps inform chemistry models: Cell line in Mice translation to Human in pancreatic cancer cell line Pessimistic view: Long way to go end point most time
Rachel Hodos Senior AI Scientist BenevolentAI Panelist Pick Targets AI is a Possible dream trusted a drug in human
Nora Khaldi Founder and CSO Nuritas AI biological data is early while relying on that knowledge identify drug safe for human is possible I believe AI – take a molecule to humans 99% working in humans AI teated and validated in vitro
Juan Alvarez AVP, Merck High dimensional spaces sample comparison Find therapies for Humans in the absence of having Humans participating, data on human is BIASED by drugs history Drugable identify interventions translatable to Humans pathway-based
Renée Deehan-Kenney PhD, VP, QuartzBio, Precision Medicine Group Chemistry in developing drugs is complex Network biology modeling – helps inform chemistry models: Cell line in Mice translation to Human in pancreatic cancer cell line
Renée Deehan-Kenney PhD, VP, QuartzBio Precision Medicine Group technology enable company clinical data analysis of data clinical trials ML prior knowledge network biology drive inside MOA prioritize indications Chemistry in developing drugs complex
Juan Alvarez AVP, Computational and Structural Chemistry Merck metabolomics evolving proteins analyzing data access to compute power data acquisition and storage – High dimensional spaces sample comparison
Juan Alvarez AVP, Computational and Structural Chemistry Merck Drug Target identification Drug Discovery – ML since 1980s Identify molecules syntesis prediction physico space – physiological systems Transcriptomics, single cell biomarkers proteomics
Renée Deehan-Kenney PhD, VP, QuartzBio Precision Medicine Group Network biology modeling – helps inform chemistry models: Cell line in Mice translation to Human in pancreatic cancer cell line Pessimistic view: Long way to go end point most time
Rachel Hodos Senior AI Scientist BenevolentAI Panelist Pick Targets AI is a Possible dream trusted a drug in human
Nora Khaldi Founder and CSO Nuritas AI biological data is early while relying on that knowledge identify drug safe for human is possible I believe AI – take a molecule to humans 99% working in humans AI teated and validated in vitro
Thomas McCourt President Ironwood Pharmaceuticals, Inc. Clinical trials many are STUCK – solve problems calls for adoption of all companies to digital platforms Entrepreneurial spirit in Kendall square took away the prime position of CA Biotech
Thomas McCourt President Ironwood Pharmaceuticals, Inc. GI disease in Patients – My Gi Health started in NIH – symptoms of GI diseases GI entrepreneurs to build a smart e-Tool to analyze the GI Symptoms few thousand Patients
Nick Dougherty Managing Director MassChallenge HealthTech Around the World communities, MA Biotech infrastructure MassChallenge HealthTech: In Mexico, in Israel in Switzerland Becoming virtual instantly in MARCH 2020 More locations pick up scale up
Naomi Fried Founder CEO Health Innovation Strategies MA best Hospitals: MGH-BWH, Beth Israel-Lahey Clinic, Stuart BC/BS Medical Schools Clusters in Biotech & Digital Health Counsel Definition of Community changed in the COVID-19 Era
Stephen Bernstein McDermott Will & Emery LLP Virtual Bench science Life sciences Products; Deploying a compound, provider responsible for the cost or how the Reimbursement will work Consumer & Patients: Specialty Pharmacy collaborations by planning
Stephen Bernstein McDermott Will & Emery LLP Webinars and Zooms allows communication we will see more innovations – Flatten the World Greater isolation US is expected to lead collaborate is NOW home based no travel creative Virtual Clinical Trials
Kenneth Anderson Director, Multiple Myeloma Center Dana-Farber Cancer Institute Hematologic Division – African Americans Change paradigm of clinical trials Geraldine Feraro was patient at DFCI Tom Bracow patient at DFCI STEM for girls 6-12 grades
Kenneth Anderson Director, Multiple Myeloma Center Dana-Farber Cancer Institute Multiple Myeloma – 23 drugs approved by FDA Dana-Farber Cancer Institute with Sanofi collaboration Foundations stepped forward to study Multiple Myeloma FDA motivated
Juan Alvarez AVP, Merck High dimensional spaces sample comparison Find therapies for Humans in the absence of having Humans participating, data on human is BIASED by drugs history Drugable identify interventions translatable to Humans pathway-based
Renée Deehan-Kenney PhD, VP, QuartzBio, Precision Medicine Group Chemistry in developing drugs is complex Network biology modeling – helps inform chemistry models: Cell line in Mice translation to Human in pancreatic cancer cell line
Renée Deehan-Kenney PhD, VP, QuartzBio Precision Medicine Group technology enable company clinical data analysis of data clinical trials ML prior knowledge network biology drive inside MOA prioritize indications Chemistry in developing drugs complex
Juan Alvarez AVP, Computational and Structural Chemistry Merck metabolomics evolving proteins analyzing data access to compute power data acquisition and storage – High dimensional spaces sample comparison
Juan Alvarez AVP, Computational and Structural Chemistry Merck Drug Target identification Drug Discovery – ML since 1980s Identify molecules syntesis prediction physico space – physiological systems Transcriptomics, single cell biomarkers proteomics
Leave a Reply